ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 82 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.89 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,176 | -61.8% | 37,934 | -90.2% | 0.00% | – |
| Q2 2023 | $126,274 | -24.2% | 387,346 | 0.0% | 0.00% | – |
| Q1 2023 | $166,558 | +81147.8% | 387,346 | 0.0% | 0.00% | – |
| Q4 2022 | $205 | -99.9% | 387,346 | -6.1% | 0.00% | – |
| Q3 2022 | $301,000 | -36.0% | 412,401 | 0.0% | 0.00% | – |
| Q2 2022 | $470,000 | -45.2% | 412,401 | -1.5% | 0.00% | – |
| Q1 2022 | $858,000 | -16.1% | 418,567 | +17.7% | 0.00% | – |
| Q4 2021 | $1,023,000 | -31.0% | 355,509 | +1.6% | 0.00% | – |
| Q3 2021 | $1,483,000 | -13.2% | 349,772 | +8.3% | 0.00% | – |
| Q2 2021 | $1,709,000 | +54.0% | 323,114 | +35.2% | 0.00% | – |
| Q1 2021 | $1,110,000 | +99.3% | 238,923 | +41.5% | 0.00% | – |
| Q4 2020 | $557,000 | +2.2% | 168,810 | +2.4% | 0.00% | – |
| Q3 2020 | $545,000 | -3.4% | 164,909 | -1.5% | 0.00% | – |
| Q2 2020 | $564,000 | -50.8% | 167,375 | -44.1% | 0.00% | – |
| Q1 2020 | $1,146,000 | -66.0% | 299,414 | -46.4% | 0.00% | – |
| Q4 2019 | $3,374,000 | +62.4% | 558,998 | +103.5% | 0.00% | – |
| Q3 2019 | $2,077,000 | -40.6% | 274,750 | +6.4% | 0.00% | -100.0% |
| Q2 2019 | $3,497,000 | +524.5% | 258,109 | +149.4% | 0.00% | – |
| Q1 2019 | $560,000 | -7.0% | 103,475 | -49.1% | 0.00% | – |
| Q4 2018 | $602,000 | -27.9% | 203,294 | +98.3% | 0.00% | – |
| Q3 2018 | $835,000 | +13.1% | 102,500 | +35.2% | 0.00% | – |
| Q2 2018 | $738,000 | -16.1% | 75,787 | -25.2% | 0.00% | – |
| Q1 2018 | $880,000 | -29.8% | 101,302 | +1.1% | 0.00% | – |
| Q4 2017 | $1,254,000 | +53.9% | 100,207 | +2.7% | 0.00% | – |
| Q3 2017 | $815,000 | -50.0% | 97,582 | +1.5% | 0.00% | -100.0% |
| Q2 2017 | $1,631,000 | +6.8% | 96,145 | +26.5% | 0.00% | 0.0% |
| Q1 2017 | $1,527,000 | +103.3% | 76,015 | +57.6% | 0.00% | – |
| Q4 2016 | $751,000 | +24.1% | 48,226 | +4.0% | 0.00% | – |
| Q3 2016 | $605,000 | +646.9% | 46,393 | +290.6% | 0.00% | – |
| Q2 2016 | $81,000 | -42.1% | 11,876 | -19.9% | 0.00% | – |
| Q1 2016 | $140,000 | -6.0% | 14,829 | -0.2% | 0.00% | – |
| Q4 2015 | $149,000 | -21.6% | 14,854 | +11.6% | 0.00% | – |
| Q3 2015 | $190,000 | – | 13,309 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |